Rhythm Pharmaceuticals, Inc. RYTM Issuance of common stock for the acquisition of Ansys

Issuance of common stock for the acquisition of Ansys at other companies

Apogee Therapeutics, Inc.APGE

——

Revenue$60.1M+83.8%

Gross profit$53.0M+82.3%

Operating income-$52.4M-11.4%

Net income-$55.6M-12.4%

EPS (diluted)-$0.83-2.5%

Cash & equivalents$62.1M-41.4%

Total debt$112.3M-1.1%

Total equity$122.9M+549%

Total assets$442.3M+14.4%

Operating cash flow-$44.2M-9.5%

CapEx$238.3K—

Free cash flow-$29.2M-2.4%

Market cap$6.64B+77.3%

Enterprise value$6.69B+78.4%

P/S30.6×+3.2×

Gross margin89.4%-0.2pp

Operating margin-90.9%-19.8pp

Net margin-93.3%-18.2pp

FCF margin-61.5%-14.1pp

Return on equity-285.8%-68.9pp

Debt / equity0.9×-5.1×

Current ratio4.2×+0.9×

Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockIssued1.

The official record: Rhythm Pharmaceuticals, Inc.’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Rhythm Pharmaceuticals, Inc.'s issuance of common stock for the acquisition of ansys?: Rhythm Pharmaceuticals, Inc. (RYTM) reported issuance of common stock for the acquisition of ansys of $0 in Q4 2025.
How has Rhythm Pharmaceuticals, Inc.'s issuance of common stock for the acquisition of ansys changed year-over-year?: Rhythm Pharmaceuticals, Inc.'s issuance of common stock for the acquisition of ansys decreased by 100.0% year-over-year, from $4.68M to $0.